Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Comparative, Open-label, Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Mefloquine (250mg) Plus Artesunate (100mg) in Children & Adult Patients With Acute Falciparum Malaria

NCT00403260 is registered in ClinicalTrials.gov with Medicines for Malaria Venture as lead sponsor.

NCT NCT00403260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00403260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Comparative, Open-label, Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Mefloquine (250mg) Plus Artesunate (100mg) in Children & Adult Patients With Acute Falciparum Malaria
Lead sponsor
Medicines for Malaria Venture
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2007
Completion date
December 31, 2008
Enrollment
1,271 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

falciparum malaria